Graft-Versus-Host Disease Market 2027 by Product Type inhibitors, Treatment Type, End User and Geography | The Insight Partners

Graft-Versus-Host Disease (GVHD) Market to 2027 - Global Analysis and Forecasts By Product Type ( Corticosteroids, ATG therapies, IL2Rα (CD25) inhibitors, TNFα inhibitors, Calcineurin inhibitors, mTOR inhibitors, SOT therapies, Anti-neoplastic therapies, Stem Cell Treatments, Extracorporeal Photophoresis, Other biologics ); Treatment Type ( Prophylaxis GVHD, Chronic GVHD, Acute GVHD ); End User ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ) and Geography

Report Code: TIPRE00006856 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

MARKET INTRODUCTION

Graft-versus-host disease (GVHD) is a medical condition which occurs after transplant surgeries where the immune cells from the donor attack on the recipient's organ tissues. This condition is a common side effect that is observed after an allogeneic bone marrow transplant (stem cell transplant). The symptoms of the disease can be from mild to severe and life-threatening and often causes diseases like jaundice, skin inflammation and others.

MARKET DYNAMICS

The graft-versus-host disease (GVHD) market is anticipated to grow in the forecast, owing increasing demand for bone marrow transplants, rising prevalence of cancer and increasing allogeneic hematopoietic stem cell transplant. In addition, growing awareness for cellular therapies is expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE

The "Graft-Versus-Host Disease (GVHD) Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of Graft-Versus-Host Disease (GVHD) market with detailed market segmentation by product type, treatment type, end user and geography. The Graft-Versus-Host Disease (GVHD) market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Graft-Versus-Host Disease (GVHD) market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The graft-versus-host disease (GVHD) market is segmented on the basis of product type, treatment type, and end user. Based on product type the market is segmented as corticosteroids, ATG therapies, IL2Rα (CD25) inhibitors, TNFα inhibitors, Calcineurin inhibitors, mTOR inhibitors, SOT therapies, anti-neoplastic therapies, stem cell treatments, extracorporeal photophoresis and other biologics. On the basis of treatment type the market is segmented into prophylaxis GVHD, chronic GVHD, acute GVHD. The end user segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the graft-versus-host disease (GVHD) market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The graft-versus-host disease (GVHD) market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting graft-versus-host disease (GVHD) market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the graft-versus-host disease (GVHD) market in these regions.
 
MARKET PLAYERS


The report covers key developments in the graft-versus-host disease (GVHD) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from graft-versus-host disease (GVHD) market are anticipated to have lucrative growth opportunities in the future with the rising demand for graft-versus-host disease (GVHD) market in the global market. Below mentioned is the list of few companies engaged in the graft-versus-host disease (GVHD) market.

The report also includes the profiles of key graft-versus-host disease (GVHD) market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  • Novartis AG
  • BristolMyers Squibb
  • Pfizer
  • F. HoffmannLa Roche
  • AbbVie
  • Astellas Pharma
  • Merck & Co
  • Takeda Pharmaceutical
  • Abbott
  • Eli Lilly.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
 

 

TABLE OF CONTENTS

1. INTRODUCTION
 1.1. SCOPE OF THE STUDY
 1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
 1.3. MARKET SEGMENTATION
 1.3.1 Graft-Versus-Host Disease (GVHD) Market - By Product Type
 1.3.2 Graft-Versus-Host Disease (GVHD) Market - By Treatment Type
 1.3.3 Graft-Versus-Host Disease (GVHD) Market - By End User
 1.3.4 Graft-Versus-Host Disease (GVHD) Market - By Region
 1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET LANDSCAPE
 4.1. OVERVIEW
 4.2. PEST ANALYSIS
 4.2.1 North America - Pest Analysis
 4.2.2 Europe - Pest Analysis
 4.2.3 Asia-Pacific - Pest Analysis
 4.2.4 Middle East and Africa - Pest Analysis
 4.2.5 South and Central America - Pest Analysis
 4.3. EXPERT OPINIONS

5. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET - KEY MARKET DYNAMICS
 5.1. KEY MARKET DRIVERS
 5.2. KEY MARKET RESTRAINTS
 5.3. KEY MARKET OPPORTUNITIES
 5.4. FUTURE TRENDS
 5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS


6. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET - GLOBAL MARKET ANALYSIS
 6.1. GRAFT-VERSUS-HOST DISEASE (GVHD) - GLOBAL MARKET OVERVIEW
 6.2. GRAFT-VERSUS-HOST DISEASE (GVHD) - GLOBAL MARKET AND FORECAST TO 2027
 6.3. MARKET POSITIONING/MARKET SHARE

7. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT TYPE
 7.1. OVERVIEW
 7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
 7.3. CORTICOSTEROIDS
 7.3.1. Overview
 7.3.2. Corticosteroids Market Forecast and Analysis
 7.4. ATG THERAPIES
 7.4.1. Overview
 7.4.2. ATG therapies Market Forecast and Analysis
 7.5. IL2Rα (CD25) INHIBITORS
 7.5.1. Overview
 7.5.2. IL2Rα (CD25) inhibitors Market Forecast and Analysis
 7.6. TNFΑ INHIBITORS
 7.6.1. Overview
 7.6.2. TNFα inhibitors Market Forecast and Analysis
 7.7. CALCINEURIN INHIBITORS
 7.7.1. Overview
 7.7.2. Calcineurin inhibitors Market Forecast and Analysis
 7.8. MTOR INHIBITORS
 7.8.1. Overview
 7.8.2. mTOR inhibitors Market Forecast and Analysis
 7.9. SOT THERAPIES
 7.9.1. Overview
 7.9.2. SOT therapies Market Forecast and Analysis
 7.10. ANTI-NEOPLASTIC THERAPIES
 7.10.1. Overview
 7.10.2. Anti-neoplastic therapies Market Forecast and Analysis
 7.11. STEM CELL TREATMENTS
 7.11.1. Overview
 7.11.2. Stem Cell Treatments Market Forecast and Analysis
 7.12. EXTRACORPOREAL PHOTOPHORESIS
 7.12.1. Overview
 7.12.2. Extracorporeal Photophoresis Market Forecast and Analysis
 7.13. OTHER BIOLOGICS
 7.13.1. Overview
 7.13.2. Other biologics Market Forecast and Analysis

8. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT TYPE
 8.1. OVERVIEW
 8.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
 8.3. PROPHYLAXIS GVHD
 8.3.1. Overview
 8.3.2. Prophylaxis GVHD Market Forecast and Analysis
 8.4. CHRONIC GVHD
 8.4.1. Overview
 8.4.2. Chronic GVHD Market Forecast and Analysis
 8.5. ACUTE GVHD
 8.5.1. Overview
 8.5.2. Acute GVHD Market Forecast and Analysis

9. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET - REVENUE AND FORECASTS TO 2027 - END USER
 9.1. OVERVIEW
 9.2. END USER MARKET FORECASTS AND ANALYSIS
 9.3. HOSPITAL PHARMACIES
 9.3.1. Overview
 9.3.2. Hospital Pharmacies Market Forecast and Analysis
 9.4. RETAIL PHARMACIES
 9.4.1. Overview
 9.4.2. Retail Pharmacies Market Forecast and Analysis
 9.5. ONLINE PHARMACIES
 9.5.1. Overview
 9.5.2. Online Pharmacies Market Forecast and Analysis

10. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
 10.1. NORTH AMERICA
 10.1.1 North America Graft-Versus-Host Disease (GVHD) Market Overview
 10.1.2 North America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis
 10.1.3 North America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Product Type
 10.1.4 North America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Treatment Type
 10.1.5 North America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By End User
 10.1.6 North America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Countries
 10.1.6.1 United States Graft-Versus-Host Disease (GVHD) Market
 10.1.6.1.1 United States Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.1.6.1.2 United States Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.1.6.1.3 United States Graft-Versus-Host Disease (GVHD) Market by End User
 10.1.6.2 Canada Graft-Versus-Host Disease (GVHD) Market
 10.1.6.2.1 Canada Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.1.6.2.2 Canada Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.1.6.2.3 Canada Graft-Versus-Host Disease (GVHD) Market by End User
 10.1.6.3 Mexico Graft-Versus-Host Disease (GVHD) Market
 10.1.6.3.1 Mexico Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.1.6.3.2 Mexico Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.1.6.3.3 Mexico Graft-Versus-Host Disease (GVHD) Market by End User
 10.2. EUROPE
 10.2.1 Europe Graft-Versus-Host Disease (GVHD) Market Overview
 10.2.2 Europe Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis
 10.2.3 Europe Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Product Type
 10.2.4 Europe Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Treatment Type
 10.2.5 Europe Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By End User
 10.2.6 Europe Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Countries
 10.2.6.1 Germany Graft-Versus-Host Disease (GVHD) Market
 10.2.6.1.1 Germany Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.2.6.1.2 Germany Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.2.6.1.3 Germany Graft-Versus-Host Disease (GVHD) Market by End User
 10.2.6.2 France Graft-Versus-Host Disease (GVHD) Market
 10.2.6.2.1 France Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.2.6.2.2 France Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.2.6.2.3 France Graft-Versus-Host Disease (GVHD) Market by End User
 10.2.6.3 Italy Graft-Versus-Host Disease (GVHD) Market
 10.2.6.3.1 Italy Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.2.6.3.2 Italy Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.2.6.3.3 Italy Graft-Versus-Host Disease (GVHD) Market by End User
 10.2.6.4 Spain Graft-Versus-Host Disease (GVHD) Market
 10.2.6.4.1 Spain Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.2.6.4.2 Spain Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.2.6.4.3 Spain Graft-Versus-Host Disease (GVHD) Market by End User
 10.2.6.5 United Kingdom Graft-Versus-Host Disease (GVHD) Market
 10.2.6.5.1 United Kingdom Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.2.6.5.2 United Kingdom Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.2.6.5.3 United Kingdom Graft-Versus-Host Disease (GVHD) Market by End User
 10.3. ASIA-PACIFIC
 10.3.1 Asia-Pacific Graft-Versus-Host Disease (GVHD) Market Overview
 10.3.2 Asia-Pacific Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis
 10.3.3 Asia-Pacific Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Product Type
 10.3.4 Asia-Pacific Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Treatment Type
 10.3.5 Asia-Pacific Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By End User
 10.3.6 Asia-Pacific Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Countries
 10.3.6.1 Australia Graft-Versus-Host Disease (GVHD) Market
 10.3.6.1.1 Australia Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.3.6.1.2 Australia Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.3.6.1.3 Australia Graft-Versus-Host Disease (GVHD) Market by End User
 10.3.6.2 China Graft-Versus-Host Disease (GVHD) Market
 10.3.6.2.1 China Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.3.6.2.2 China Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.3.6.2.3 China Graft-Versus-Host Disease (GVHD) Market by End User
 10.3.6.3 India Graft-Versus-Host Disease (GVHD) Market
 10.3.6.3.1 India Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.3.6.3.2 India Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.3.6.3.3 India Graft-Versus-Host Disease (GVHD) Market by End User
 10.3.6.4 Japan Graft-Versus-Host Disease (GVHD) Market
 10.3.6.4.1 Japan Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.3.6.4.2 Japan Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.3.6.4.3 Japan Graft-Versus-Host Disease (GVHD) Market by End User
 10.3.6.5 South Korea Graft-Versus-Host Disease (GVHD) Market
 10.3.6.5.1 South Korea Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.3.6.5.2 South Korea Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.3.6.5.3 South Korea Graft-Versus-Host Disease (GVHD) Market by End User
 10.4. MIDDLE EAST AND AFRICA
 10.4.1 Middle East and Africa Graft-Versus-Host Disease (GVHD) Market Overview
 10.4.2 Middle East and Africa Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis
 10.4.3 Middle East and Africa Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Product Type
 10.4.4 Middle East and Africa Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Treatment Type
 10.4.5 Middle East and Africa Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By End User
 10.4.6 Middle East and Africa Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Countries
 10.4.6.1 South Africa Graft-Versus-Host Disease (GVHD) Market
 10.4.6.1.1 South Africa Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.4.6.1.2 South Africa Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.4.6.1.3 South Africa Graft-Versus-Host Disease (GVHD) Market by End User
 10.4.6.2 Saudi Arabia Graft-Versus-Host Disease (GVHD) Market
 10.4.6.2.1 Saudi Arabia Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.4.6.2.2 Saudi Arabia Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.4.6.2.3 Saudi Arabia Graft-Versus-Host Disease (GVHD) Market by End User
 10.4.6.3 U.A.E Graft-Versus-Host Disease (GVHD) Market
 10.4.6.3.1 U.A.E Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.4.6.3.2 U.A.E Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.4.6.3.3 U.A.E Graft-Versus-Host Disease (GVHD) Market by End User
 10.5. SOUTH AND CENTRAL AMERICA
 10.5.1 South and Central America Graft-Versus-Host Disease (GVHD) Market Overview
 10.5.2 South and Central America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis
 10.5.3 South and Central America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Product Type
 10.5.4 South and Central America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Treatment Type
 10.5.5 South and Central America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By End User
 10.5.6 South and Central America Graft-Versus-Host Disease (GVHD) Market Forecasts and Analysis - By Countries
 10.5.6.1 Brazil Graft-Versus-Host Disease (GVHD) Market
 10.5.6.1.1 Brazil Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.5.6.1.2 Brazil Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.5.6.1.3 Brazil Graft-Versus-Host Disease (GVHD) Market by End User
 10.5.6.2 Argentina Graft-Versus-Host Disease (GVHD) Market
 10.5.6.2.1 Argentina Graft-Versus-Host Disease (GVHD) Market by Product Type
 10.5.6.2.2 Argentina Graft-Versus-Host Disease (GVHD) Market by Treatment Type
 10.5.6.2.3 Argentina Graft-Versus-Host Disease (GVHD) Market by End User

11. INDUSTRY LANDSCAPE
 11.1. MERGERS AND ACQUISITIONS
 11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
 11.3. NEW PRODUCT LAUNCHES
 11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET, KEY COMPANY PROFILES
 12.1. NOVARTIS AG
 12.1.1. Key Facts
 12.1.2. Business Description
 12.1.3. Products and Services
 12.1.4. Financial Overview
 12.1.5. SWOT Analysis
 12.1.6. Key Developments
 12.2. BRISTOL-MYERS SQUIBB
 12.2.1. Key Facts
 12.2.2. Business Description
 12.2.3. Products and Services
 12.2.4. Financial Overview
 12.2.5. SWOT Analysis
 12.2.6. Key Developments
 12.3. PFIZER
 12.3.1. Key Facts
 12.3.2. Business Description
 12.3.3. Products and Services
 12.3.4. Financial Overview
 12.3.5. SWOT Analysis
 12.3.6. Key Developments
 12.4. F. HOFFMANN-LA ROCHE
 12.4.1. Key Facts
 12.4.2. Business Description
 12.4.3. Products and Services
 12.4.4. Financial Overview
 12.4.5. SWOT Analysis
 12.4.6. Key Developments
 12.5. ABBVIE
 12.5.1. Key Facts
 12.5.2. Business Description
 12.5.3. Products and Services
 12.5.4. Financial Overview
 12.5.5. SWOT Analysis
 12.5.6. Key Developments
 12.6. ASTELLAS PHARMA
 12.6.1. Key Facts
 12.6.2. Business Description
 12.6.3. Products and Services
 12.6.4. Financial Overview
 12.6.5. SWOT Analysis
 12.6.6. Key Developments
 12.7. MERCK AND CO.
 12.7.1. Key Facts
 12.7.2. Business Description
 12.7.3. Products and Services
 12.7.4. Financial Overview
 12.7.5. SWOT Analysis
 12.7.6. Key Developments
 12.8. TAKEDA PHARMACEUTICAL
 12.8.1. Key Facts
 12.8.2. Business Description
 12.8.3. Products and Services
 12.8.4. Financial Overview
 12.8.5. SWOT Analysis
 12.8.6. Key Developments
 12.9. ABBOTT
 12.9.1. Key Facts
 12.9.2. Business Description
 12.9.3. Products and Services
 12.9.4. Financial Overview
 12.9.5. SWOT Analysis
 12.9.6. Key Developments
 12.10. ELI LILLY.
 12.10.1. Key Facts
 12.10.2. Business Description
 12.10.3. Products and Services
 12.10.4. Financial Overview
 12.10.5. SWOT Analysis
 12.10.6. Key Developments

13. APPENDIX
 13.1. ABOUT THE INSIGHT PARTNERS
 13.2. GLOSSARY OF TERMS

 

The List of Companies

1. Novartis AG
2. Bristol-Myers Squibb
3. Pfizer
4. F. Hoffmann-La Roche
5. AbbVie
6. Astellas Pharma
7. Merck & Co
8. Takeda Pharmaceutical
9. Abbott
10. Eli Lilly.